Tower Research Capital (TRC)’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,997
| Closed | -$1.59K | – | 5692 |
|
|
2025
Q1 | $1.59K | Buy |
+2,997
| New | +$4.94K | ﹤0.01% | 4687 |
|
|
2024
Q4 | – | Sell |
-349
| Closed | -$5K | – | 6098 |
|
|
2024
Q3 | $5K | Sell |
349
-46
| -12% | -$631 | ﹤0.01% | 4345 |
|
|
2024
Q2 | $6.4K | Buy |
395
+168
| +74% | +$4.22K | ﹤0.01% | 4585 |
|
|
2024
Q1 | $23K | Sell |
227
-40
| -15% | -$2.53K | ﹤0.01% | 2877 |
|
|
2023
Q4 | $6.31K | Sell |
267
-92
| -26% | -$1.55K | ﹤0.01% | 4760 |
|
|
2023
Q3 | $7.25K | Buy |
359
+150
| +72% | +$2.91K | ﹤0.01% | 4488 |
|
|
2023
Q2 | $5.42K | Buy |
209
+61
| +41% | +$1.75K | ﹤0.01% | 4831 |
|
|
2023
Q1 | $3K | Buy |
148
+15
| +11% | +$336 | ﹤0.01% | 5264 |
|
|
2022
Q4 | $3K | Buy |
133
+131
| +6,550% | +$2.47K | ﹤0.01% | 5261 |
|
|
2022
Q3 | $0 | Sell |
2
-336
| -99% | -$9.67K | ﹤0.01% | 6585 |
|
|
2022
Q2 | $9K | Buy |
338
+215
| +175% | +$9.56K | ﹤0.01% | 4604 |
|
|
2022
Q1 | $10K | Buy |
123
+63
| +105% | +$7.78K | ﹤0.01% | 4372 |
|
|
2021
Q4 | $12K | Buy |
60
+29
| +94% | +$7.24K | ﹤0.01% | 4345 |
|
|
2021
Q3 | $10K | Buy |
31
+29
| +1,450% | +$8.46K | ﹤0.01% | 4351 |
|
|
2021
Q2 | $0 | Sell |
2
-6
| -75% | -$1.83K | ﹤0.01% | 5930 |
|
|
2021
Q1 | $3K | Buy |
+8
| New | +$3.23K | ﹤0.01% | 4941 |
|
Other funds holding VINC
Tower Research Capital (TRC)'s VINC Position: Q2 2025 in Review
Tower Research Capital (TRC) sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2025, closing a stake of 2,997 shares — an estimated $1.59K sold.
Tower Research Capital (TRC) first reported a position in VINC in Q1 2021 and held it in 16 quarters. The position peaked at $23K in Q1 2024. 1 fund tracked by Wall St. Rank holds VINC as of Q2 2025.
- Tower Research Capital (TRC) reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 2,997 Vincerx Pharma, Inc. Common Stock shares in Q2 2025, an estimated $1.59K.
- Tower Research Capital (TRC) first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2021 and held it in 16 quarters.
- Tower Research Capital (TRC)'s Vincerx Pharma, Inc. Common Stock position peaked at $23K in Q1 2024.
- 1 fund tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.